Mode
Text Size
Log in / Sign up
N/A Completed N=2,974

A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)

Source: ClinicalTrials.gov NCT01354990 ↗
Enrolled (actual)
2,974
Serious AEs
0.0%
Results posted
Jun 2012
Primary outcomePrimary: Number of Participants With an Adverse Event — 25 participants

Summary

The primary objective of this study is to obtain safety information on the use of sitagliptin (JANUVIA®) from endocrinologists, diabetologists, internists, and general practitioners.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With an Adverse Event
25 —
PRIMARY
Age of Participants Prescribed Sitagliptin
55 —
PRIMARY
Number of Participants With Concomitant Therapies
1878 —
PRIMARY
Number of Participants With Concomitant Conditions
752 —

Eligibility Criteria

Inclusion Criteria

  • Must be taking sitagliptin (JANUVIA™) for the treatment of type 2 diabetes

mellitus

  • Treating physician must agree to provide information regarding the participants treatment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01354990). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search